Lexmark, a global imaging solutions leader, today announced a partnership with NHS Shared Business Services (NHS SBS) to enable the public sector to utilise Lexmark technology to support their aim of meeting paperless and digital targets, whilst delivering savings, efficiencies and improving patient care. The framework allows Lexmark to integrate hardware and software platforms to drive interoperability and 'paperlight' working environments within the Public Sector.

Participate in the first ever ESC Digital Health Call for Technology, for the chance to present your innovations, your technology or your products at ESC Congress 2018 in front of an audience of relevant professionals. A dedicated Digital Health Area will feature a stage setting surrounded by Industry booths and meeting facilities, providing opportunities to exchange on latest digital health related innovations and research.

Today, the FDA is opening a docket to solicit feedback on important provisions of the 21st Century Cures Act ("Cures Act"). The Cures Act amended the Federal Food, Drug, and Cosmetic Act to exclude certain medical software functions from the definition of a medical device. Under the Cures Act, Congress excluded specific types of software from FDA regulation, including general wellness software products, electronic patient records and more.

The Master of Science Program in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule Deggendorf) in Bavaria, Germany - is accepting applications for entry in October 2018.

Founded in 2013 in Berlin initially giving out grants to innovative healthcare apps, G4A Accelerator is now a global program dedicated to helping innovative health & care startups grow and enable positive disruption and progress within the digital health & care universe.

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments.

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes. Diabetic retinopathy occurs when high levels of blood sugar lead to damage in the blood vessels of the retina, the light-sensitive tissue in the back of the eye.